Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: There are few studies in the literature on the dosage of statin that equivalently reduces low-density lipoprotein cholesterol (LDL-C) compared to an ezetimibe combination and whether such regimens have differences in safety. We compared the lipid modifying efficacy and safety of 5 mg rosuvastatin/10 mg ezetimibe to those of 20 mg rosuvastatin. Materials and Methods: A literature search was conducted using the PubMed, EMBASE, Cochrane, Web of Sciences, and SCOPUS databases up to December 2021. Human studies investigating the two aforementioned regimens with a randomized controlled de sign were selected. Outcome variables included the percentage reduction in LDL-C and other lipid parameters and rates of com posite adverse events (AEs), including muscle-related symptoms. A random-effects meta-analysis was performed after heteroge neity testing between studies. Results: Seven studies were included in this meta-analysis. The percentage LDL-C reduction did not differ between the combina tion and monotherapy groups [standardized mean difference (SMD) 0.08; 95% confidence interval (CI) -0.09 to 0.26; p=0.35]. The risk of composite AEs (odds ratio 0.50; 95% CI 0.15 to 1.72; p=0.27) of the combination was not different compared to the mono therapy group. The percentage of total cholesterol reduction was greater in the combination group (SMD 0.22; p=0.02), whereas that of triglyceride reduction and high-density lipoprotein cholesterol elevation did not differ between the two groups. Conclusion: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.
Abstract
Purpose: There are few studies in the literature on the dosage of statin that equivalently reduces low-density lipoprotein cholesterol (LDL-C) compared to an ezetimibe combination and whether such regimens have differences in safety. We compared the lipid modifying efficacy and safety of 5 mg rosuvastatin/10 mg ezetimibe to those of 20 mg rosuvastatin. Materials and Methods: A literature search was conducted using the PubMed, EMBASE, Cochrane, Web of Sciences, and SCOPUS databases up to December 2021. Human studies investigating the two aforementioned regimens with a randomized controlled de sign were selected. Outcome variables included the percentage reduction in LDL-C and other lipid parameters and rates of com posite adverse events (AEs), including muscle-related symptoms. A random-effects meta-analysis was performed after heteroge neity testing between studies. Results: Seven studies were included in this meta-analysis. The percentage LDL-C reduction did not differ between the combina tion and monotherapy groups [standardized mean difference (SMD) 0.08; 95% confidence interval (CI) -0.09 to 0.26; p=0.35]. The risk of composite AEs (odds ratio 0.50; 95% CI 0.15 to 1.72; p=0.27) of the combination was not different compared to the mono therapy group. The percentage of total cholesterol reduction was greater in the combination group (SMD 0.22; p=0.02), whereas that of triglyceride reduction and high-density lipoprotein cholesterol elevation did not differ between the two groups. Conclusion: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.
참고문헌 (25)
- Razavi AC, "Statin therapy for the primary prevention of cardiovascular disease : pros", Atherosclerosis, 356, pp.41~45 (2022)
- Kim GS, "Impact of statin treatment intensity after endovascular revascularization on lower extremity peripheral artery disease", Yonsei Med J, 63, pp.333~341 (2022)
- Yang YS, "Lipid management in Korean people with type 2 diabetes mellitus : Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement", J Lipid Atheroscler, 12, pp.12~22 (2023)
- Lee CJ, "2022consensus statement on the management of familial hypercholesterolemia in Korea", J Lipid Atheroscler, 11, pp.213~228 (2022)
- Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
- Authors, "Task Force Members", 2019 ESC, Atherosclerosis, pp.2019, 290[DOI]
- Her AY, "Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin", ezetimibe 5 mg, J Cardiovasc Pharmacol Ther, pp.2010, 15[DOI]
- Lee SH, "The effects of statin monotherapy and low-dose statin", ezetimibe on lipoprotein-associated phospholipase A₂, 2011, pp.34, 108~112
- Kim BK, "Longterm efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease(RACING) : a randomised, open-label, non-inferiority trial", Lancet, 400, pp.380~390 (2022)
- LaRosa JC, "Intensive lipid lowering with atorvastatin in patients with stable coronary disease", N Engl J Med, 352, pp.1425~1435 (2005)
- Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372, pp.2387~2397 (2015)
- Moher D, "Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement", BMJ, 339, pp.b2535~ (2009)
- Hozo SP, "Estimating the mean and variance from the median, range, and the size of a sample", BMC Med Res Methodol, 5, pp.13~ (2005)
- Hwang YC, "Comparison of the efficacy of rosuvastatin monotherapy 20 mg with rosuvastatin 5 mg and ezetimibe 10 mg combination therapy on lipid parameters in patients with type 2 diabetes mellitus", Diabetes Metab J, 43, pp.582~589 (2019)
- Rhee MY, "Ezetimibe and rosuvastatin combination treatment can reduce the dose of rosuvastatin without compromising its lipid-lowering efficacy", Clin Ther, 41, pp.2571~2592 (2019)
- Hong SJ, "A phase III, multicenter, randomized, double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia : I-ROSETTE(Ildong rosuvastatin & ezetimibe for hypercholesterolemia)randomized controlled trial", Clin Ther, 40, pp.226~241 (2018)
- Kim W, "Efficacy and safety of ezetimibe and rosuvastatin combination therapy versus those of rosuvastatin monotherapy in patients with primary hypercholesterolemia", Clin Ther, 40, pp.993~1013 (2018)
- Yang YJ, "Combination therapy of rosuvastatin and ezetimibe in patients with high cardiovascular risk", Clin Ther, 39, pp.107~117 (2017)
- Oh M, "Comparison of high-dose rosuvastatin versus low-dose rosuvastatin plus ezetimibe on carotid atherosclerotic plaque inflammation in patients with acute coronary syndrome", J Cardiovasc Transl Res, 13, pp.900~907 (2020)
- Bays HE, "Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia(the ACTE Study)", Am J Cardiol, 108, pp.523~530 (2011)
- Yu M, "Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia : a metaanalysis of literature", Lipids Health Dis, 19, pp.1~ (2020)
- Yamazaki D, "Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadrupledose rosuvastatin and rosuvastatin combined with ezetimibe", Lipids Health Dis, 12, pp.9~ (2013)
- Zhu Y, "The efficacy and safety of statin in combination with ezetimibe compared with doubledose statin in patients with high cardiovascular risk : a meta-analysis", Bosn J Basic Med Sci, 20, pp.169~182 (2020)
- Kim J, "Moderateintensity statins plus ezetimibe vs. high-intensity statins after coronary revascularization : a cohort study", Cardiovasc Drugs Ther, 37, pp.141~150 (2023)
- Cha JJ, "Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease : rationale and design of a randomized, controlled SaveSAMS trial", Am Heart J, 261, pp.45~50 (2023)